Bigul

Venus Remedies Ltd - 526953 - Board Meeting Intimation for To Consider And Approve Audited Financial Results For The Quarter And Year Ended On 31St March 2021 And Allotment Of 10,25,000 Equity Shares On Conversion Of Fully Convertible Warrants.

VENUS REMEDIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 31/05/2021 ,inter alia, to consider and approve This is to inform you that the meeting of Board of Directors is scheduled to be held on 31st May 2021 to inter alia consider and approve as below: 1 To consider and approve Audited Financial Results for the quarter and year ended on 31st March 2021. 2 To consider and approve the allotment of 10,25,000 equity shares on conversion of 10,25,000 fully convertible warrants. 3 Any other business with the permission of Chair.
24-05-2021
Bigul

Venus Remedies Ltd - 526953 - For The Period Ending On 31St March 2021.

For the period ending on 31st March 2021.
22-04-2021
Bigul

VENUS REMEDIES LTD. - 526953 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

Venus Remedies Enters into Partnership with West Pharmaceutical Services, Inc. to Launch Cloti-Xa(tm) (Enoxaparin Prefilled Syringes) in India with NovaGuard(r) SA Pro Safety System.
13-04-2021
Bigul

VENUS REMEDIES LTD. - 526953 - For The Half Year Ended On 31.03.2021

For the half year ended on 31.03.2021
13-04-2021
Bigul

Venus Remedies Ltd - 526953 - Statement Of Investor Complaints For The Quarter Ended March 2021

No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 041410 Name of the Signatory :- NehaDesignation :- Company Secretary and Compliance Officer
13-04-2021
Bigul

Venus Remedies Ltd - 526953 - Shareholding for the Period Ended March 31, 2021

Venus Remedies Ltd has submitted to BSE the Shareholding Pattern for the Period Ended March 31, 2021. For more details, kindly Click here
06-04-2021
Bigul

VENUS REMEDIES LTD. - 526953 - Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.

The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on April 01, 2021 for Suven Pharma Solutions Ltd
01-04-2021
Bigul

Venus Remedies Ltd - 526953 - Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.

The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on March 31, 2021 for Mrs Manu Chaudhary & Pawan Chaudhary
31-03-2021
Bigul

Venus Remedies Ltd - 526953 - Closure of Trading Window

Pursuant to the Code of Conduct adopted by the Company under SEBI (Prohibition of Insider Trading) Regulations, 2015, this is to inform that the trading window for dealing in equity shares of the Company will remain closed for all Designated Persons of the Company, as defined under the said Regulations, from April 1, 2021 till 48 hours from the declaration of the Audited Financial Results for the Quarter and year ending March 31, 2021.
30-03-2021
Next Page
Close

Let's Open Free Demat Account